Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.52 |
| ▸ | TK2 | O00142 | 4/20 | 0.52 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.50 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10178250 | 0.89 | TK1 (0.63) | TK1TK2TYMSLMNASMN1; SMN2 | |
| SCHEMBL1665228 | 0.89 | TK1 (0.63) | TK1TK2TYMSLMNASMN1; SMN2 | |
| SCHEMBL10231090 | 0.89 | TK1 (0.63) | TK1TK2TYMSLMNASMN1; SMN2 | |
| SCHEMBL1665230 | 0.89 | TK1 (0.63) | TK1TK2TYMSLMNASMN1; SMN2 | |
| SCHEMBL12150924 | 0.82 | TK1 (0.66) | TK1TK2LMNASMN1; SMN2 | |
| SCHEMBL9780916 | 0.81 | RNASE1 (0.58) | TK1TK2RNASE1 | |
| SCHEMBL9780910 | 0.81 | RNASE1 (0.58) | TK1TK2RNASE1 | |
| SCHEMBL17669967 | 0.81 | TK1 (0.63) | TK1TK2TYMSLMNASMN1; SMN2 | |
| SCHEMBL1666025 | 0.80 | TK1 (0.65) | TK1TK2LMNASMN1; SMN2 | |
| SCHEMBL13573919 | 0.80 | TK1 (0.65) | TK1TK2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | TK1 90/4885TK2 108/4885RNASE1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.